Search results
Oppenheimer Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $25.00
ETF DAILY NEWS· 3 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price objective trimmed by Oppenheimer from $50.00 to $25.00 in a report issued on Tuesday morning, Benzinga reports ...
Laika’s ‘Coraline’ returns to theaters this summer for 15th anniversary
OregonLive.com· 13 hours agoIn 2023, Fathom Events re-released “Coraline” for two days, and the movie surprised industry...
Perspective Therapeutics (NYSE:CATX) Rating Reiterated by Oppenheimer
ETF DAILY NEWS· 2 days agoPerspective Therapeutics (NYSE:CATX – Get Free Report)‘s stock had its “outperform” rating restated...
10 things to watch in the stock market Friday including more optimism on Apple's AI plan
CNBC· 21 hours agoMy top 10 things to watch Friday, June 21 Stocks are indicated for a slightly lower open Friday...
'Oppenheimer' with Alchemy Theatre
WSAZ NewsChannel 3 West Virginia· 4 days agoOpening night is Friday.
Delta Stock Is Rebounding. Its CEO Explains Why It Can Fly Higher.
Barrons.com· 16 hours agoThe airline’s chief executive, Ed Bastien, a Barron’s Top CEO, lays out how Delta recovered from a...
Oppenheimer Lowers Ovid Therapeutics (NASDAQ:OVID) to Market Perform
ETF DAILY NEWS· 4 days agoOvid Therapeutics (NASDAQ:OVID – Get Free Report) was downgraded by stock analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a report issued ...
NBCUniversal's Donna Langley on AI: ‘We’ve got to get the ethics of it right’
Los Angeles Times· 8 hours agoArtificial intelligence is “exciting,” but guardrails must be put in place to protect labor,...
Morgan Stanley says ‘crown jewel’ of Citi is worth half the bank’s value
Fortune via Yahoo Finance· 1 day agoWhile Citi’s stock has increased 14 percent this year to $60.62, analysts at Oppenheimer and Wells...
Health Care Roundup: Market Talk
The Wall Street Journal· 13 hours agoFind insight on Zealand Pharma’s petrelintide shot , Sarepta Therapeutics, EssilorLuxottica, and more in the latest Market Talks covering the Health Care...